Quantcast

New ‘Reaxys’ Solution Improves Workflow Quality and Efficiency for Chemists

January 26, 2009

FRANKFURT, Germany, January 26 /PRNewswire-FirstCall/ –

– Elsevier’s New Web-Based Solution Combines Content From the Trusted
CrossFire Databases in a Highly Intuitive and Easy to use Interface With New
Features and Functionality

Elsevier, the leading publisher of scientific, medical and technical
products and services, today introduced Reaxys, a new workflow solution for
synthetic chemists. Reaxys is based on data from Elsevier’s industry leading
chemistry databases (CrossFire Beilstein, CrossFire Gmelin and Patent
Chemistry Database) now merged together to provide harmonized content,
additional functionalities and a redesigned interface to help improve R&D
efficiency. Reaxys also contains new unique features including a synthesis
planner and advanced results handling to help scientists gather relevant
information more efficiently.

“Scientists, both in academia and industry, are under increasing pressure
to deliver more and better results in a shorter time and make research
decisions faster,” said Mark van Mierle, managing director for Elsevier
Information Systems. “Reaxys now gives them a tool to quickly create an
overview of the of synthesis design options available for their work,
research and quickly identify and select the most appropriate. By integrating
chemical reaction and substance data from trusted sources with a synthesis
design process, customers can accelerate early phase discovery.”

    Features include:

    - Workflow and decision making support for synthesis design and
      planning, e.g. by comparing alternative synthesis routes and selecting
      the most relevant paths;
    - Quick access to key data by displaying results in a unique
      tabulated overview of the most important information;
    - Convenient and flexible output of data in most common formats.

Reaxys has been developed with input and advice from development partners
from corporate and academic research institutions around the world. In
addition, the web interface has been designed by experts in human-computer
interaction. The look and feel has been streamlined to make searching easier
and provide a clear visualization of the results.

The result is a solution that goes beyond retrieving data. Search results
reflect how chemists think and work, helping their workflow move seamlessly
from initial search, recognition of possible starting materials and their
properties and through planning a strategy for the synthesis of a new
compound to proposing a detailed synthetic route. Most compounds in Reaxys
can be identified by their CAS Registry Numbers(R).

Migrating from Crossfire to Reaxys

Reaxys is available today and existing CrossFire customers may use Reaxys
in parallel for an interim period. Elsevier offers full training and helpdesk
support for new customers as well as guidance for the migration from
CrossFire to the new platform. For the time being all CrossFire products as
well as the Commander interface will be fully supported.

Select customers have been evaluating Reaxys throughout its development
and have provided positive feedback. Elsevier will continue to engage with
the chemistry community in future product development. For more information,
visit http://www.info.reaxys.com.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. Working in partnership with the
global science and health communities, Elsevier’s 7,000 employees in over 70
offices worldwide publish more than 2,000 journals and 1,900 new books per
year, in addition to offering a suite of innovative electronic products, such
as ScienceDirect (http://www.sciencedirect.com/), MD Consult
(http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/),
bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered in
Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of
Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading
publisher and information provider. Operating in the science and medical,
legal, education and business-to-business sectors, Reed Elsevier provides
high-quality and flexible information solutions to users, with increasing
emphasis on the Internet as a means of delivery. Reed Elsevier’s ticker
symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and
ENL (New York Stock Exchange).

Reaxys(TM) and CrossFire Beilstein are owned and protected by Elsevier
Properties SA and used under license.

More about the addition of CAS Registry Numbers(R) can be found in a
recent agreement between CAS (Chemical Abstract Service) and Elsevier:
http://www.info.reaxys.com/press_room.

    Tom Reller (For U.S.)
    Director, Corp. Relations
    +1-212-462-1912
    T.Reller@Elsevier.com

    Emma Potter (Europe/Asia)
    Kaizo Public Relations
    +44-(0)20-3043-4191
    EPotter@Kaizo.net

SOURCE Elsevier


Source: newswire



comments powered by Disqus